rem-422
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2023 (NCT06118086)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transcriptional activator MybANTISENSE INHIBITOR
MYB antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06297941 | Phase 1 | Apr 26, 2024 | Remix Therapeutics |
| NCT06118086 | Phase 1 | Nov 15, 2023 | Remix Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Remix Therapeutics | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1